FWK Holdings LLC v. Shire PLC et al (Direct Purchaser Antitrust Class Action Complaint)

  1. August 23, 2024

    Firms Seek $20M Fee After $58M Deal In Shire Antitrust Suit

    A group of nine firms led by Hagens Berman Sobol Shapiro LLP asked a Massachusetts federal judge to sign off on $20 million in fees and expenses after securing a $58 million settlement with drugmaker Shire PLC in a yearslong antitrust class action.

  2. May 14, 2024

    Shire Settles Claims Over Alleged ADHD Generic Delay

    Purchasers of the medication Intuniv have settled a years-old class action against drugmaker Shire PLC and manufacturer Actavis over allegations that the companies struck an anti-competitive deal to delay the production of a generic version of the attention-deficit/hyperactivity disorder drug.

  3. February 11, 2021

    ADHD Drug Buyer May Need To Arbitrate Antitrust Claims

    A Massachusetts federal court has sent the latest potential representative for a class of Intuniv buyers to arbitration to find out whether it needs to arbitrate claims that Shire PLC cut an anti-competitive deal to delay a generic version of its ADHD drug.

  4. December 10, 2020

    Judge Awards Attys $6M In Fees In Intuniv Antitrust Suit

    A Massachusetts federal judge on Wednesday awarded fees exceeding $5.9 million and costs and expenses of about $2.17 million to attorneys representing direct buyers in their claims that pharmaceutical companies Actavis and Shire schemed to stave off a generic form of the attention deficit drug Intuniv.

  5. September 23, 2020

    Shire Fights Latest Class Rep In ADHD Drug Antitrust Suit

    Shire has urged a Massachusetts federal court to reject a third potential representative for a class of direct purchasers suing over the alleged delay of a generic version of the ADHD drug Intuniv, contending the latest candidate still misses the mark.

  6. September 14, 2020

    Actavis $19M Deal In ADHD Drug Antitrust Suit Gets Initial OK

    A Massachusetts federal judge has given her initial approval of a $19.9 million settlement deal between pharmaceutical company Actavis and the direct purchaser class in a lawsuit that accused the company, along with fellow pharma company Shire, of conspiring to delay sales of a generic version of the attention deficit hyperactivity disorder medication Intuniv.

  7. August 19, 2020

    Actavis Inks Settlement In ADHD Drug Antitrust Suit

    Pharmaceutical company Actavis told a Massachusetts federal court Wednesday that it had reached a settlement with the direct purchaser class in a lawsuit that accused the company, along with fellow pharma company Shire, of conspiring to delay sales of a generic version of the attention deficit hyperactivity disorder medication Intuniv.

  8. July 08, 2020

    Wholesaler Dropped As Lead In ADHD Drug Antitrust Suit

    A Massachusetts federal judge disqualified wholesaler Rochester Drug Co-Operative from leading a class of direct purchasers accusing pharmaceutical companies Actavis and Shire of conspiring to delay sales of a generic version of the ADHD medication Intuniv.

  9. June 03, 2020

    Pharmacy Chain Says It Can Rep Class If Lead Is DQ'd

    A Midwest pharmacy chain said Tuesday that it's ready to fill in as head of a direct purchaser class accusing Actavis and Shire of illegally delaying the sale of a generic version of Shire's ADHD medication Intuniv if the pharmaceutical companies manage to decertify the class's current named plaintiff.

  10. November 06, 2019

    No Class Cert. Redo For ADHD Drug Buyers In Antitrust Suit

    A Massachusetts federal judge refused Wednesday to reconsider her denial of class certification to consumers accusing pharmaceutical companies Actavis and Shire of illegally delaying the sale of a generic version of Shire's ADHD medication Intuniv, finding the buyers still undone by a large group of uninjured buyers.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!